title: Phase II study of weekly irinotecan and carboplatin for refractory or relapsed small-cell lung cancer.
abstract: We designed a phase II study of weekly irinotecan (CPT-11) and carboplatin for refractory or relapsed small cell lung cancer (SCLC) and assessed the response rate, survival, and toxicity. Twenty-nine patients with refractory or relapsed SCLC were entered onto the trial. The median time off chemotherapy was 3.5 months (range: 0.8-12.9). Patients were treated at 4-week intervals using CPT-11 (50 mg/m(2) intravenously on days 1, 8 and 15) plus carboplatin (AUC = 2 mg/ml min, intravenously on days 1, 8, 15). All patients were assessable for toxicity and survival; 28 patients were assessable for response. There were nine partial responses (PRs). Overall response rate was 31.0% (95% CI: 15.3-50.8%). The median time to progression was 3.5 months. Median survival time was 6.1 months. Major toxicity was myelosuppression. Grade 3 to 4 neutropenia and thrombocytopenia occurred in 52 and 21% of patients, respectively. Grade 3-4 diarrhea was observed in 7%. There was one treatment-related death due to febrile neutropenia and sepsis. This combination of CPT-11 and carboplatin seems to be active second-line regimen with acceptable toxicity against small cell lung cancer.
authors.affiliation: Department of Internal Medicine, National Kinki Central Hospital for Chest Diseases, 1180 Nagasone, Sakai, Osaka 591-855, Japan. naka1@aol.com
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Naka
authors.forename: Masaaki
authors.initials: M
authors.lastname: Kawahara
authors.forename: Kyoichi
authors.initials: K
authors.lastname: Okishio
authors.forename: Shigeto
authors.initials: S
authors.lastname: Hosoe
authors.forename: Mitsumasa
authors.initials: M
authors.lastname: Ogawara
authors.forename: Shinji
authors.initials: S
authors.lastname: Atagi
authors.forename: Yuuji
authors.initials: Y
authors.lastname: Takemoto
authors.forename: Kiyonobu
authors.initials: K
authors.lastname: Ueno
authors.forename: Tomoya
authors.initials: T
authors.lastname: Kawaguchi
authors.forename: Tessei
authors.initials: T
authors.lastname: Tsuchiyama
authors.forename: Kiyoyuki
authors.initials: K
authors.lastname: Furuse
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D016190:Carboplatin / Q000008:administration & dosage; D018288:Carcinoma, Small Cell / Q000188:drug therapy* / Q000473:pathology; D018450:Disease Progression; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D000077146:Irinotecan; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced; D013534:Survival; D013921:Thrombocytopenia / Q000139:chemically induced
chemical_list: D000077146:Irinotecan; D016190:Carboplatin; D002166:Camptothecin